Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY; or 5% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.66 and Non-GAAP EPS of $1.93; Includes Net Impact of ($0.14) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges and Licensing Income Delivers Robust Revenue Growth of 11% from In-Line Products and New Product Portfolio; or 16% When Adjusted for Foreign Exchange Expands Oncology Franchise with New Indications for Opdivo and Planned Acquisition of Precision Oncology Company, Turning Point Therapeutics Strengthens Cell Therapy Franchise with Broadest Label for Breyanzi in Relapsed or Refractory Large B-cell Lymph

Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, announced today that it has entered into an exclusive license agreement with LaNova Medicines Limited (LaNova) to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and rest of the world, excluding Greater Chi

In a total of 71 TKI-naïve patients, confirmed objective response rate (cORR) of 79% (95% CI: 68, 88)In the TKI-naïve population with approximately 10 months of follow-up, initial estimated durability of response and progression free survival of 85% and 82% at 12-month landmarks, respectivelyIn TKI-pretreated patients, cORR of 42% in those treated with 1 TKI and platinum-based chemotherapy (EXP-2), cORR of 28% in those treated with two TKIs (EXP-3), and cORR of 36% in those treated with 1 TKI (EXP-4) In TKI-pretreated patients with an identified ROS1 G2032R solvent front mutation, cORR of 59%Pre-NDA meeting anticipated this quarter to discuss potential NDA in ROS1-positive NSCLC Conference C

Updated Preliminary Clinical Data Presented for Lead Drug Candidate Repotrectinib and Elzovantinib at the AACR-NCI-EORTC ConferenceMultiple FDA Interactions Anticipated in Q4 2021 and 1H 2022 for Repotrectinib and ElzovantinibCash, Cash Equivalents, and Marketable Securities of $1.0 Billion Expected to Fund Current Operations into 2024 SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the third quarter ended September 30, 2021 and provided operational updates. "We are encouraged by the progress made across

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it will report third quarter financial results following the close of U.S. financial markets on November 9. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results and provide operational updates. President and CEO Athena Countouriotis, M.D., will host the call, which will include a question and answer session. The update will be accessible via audio webcast through the "Investors" section of www.tptherapeutics.com or by dialing (877) 388

Repotrectinib Demonstrates Clinical Activity Across Multiple ROS1+ TKI-Pretreated NSCLC Cohorts, with Confirmed Objective Response Rates of 30-39 Percent in TRIDENT-1 StudyRepotrectinib Demonstrates Confirmed Objective Response Rate of 53 Percent in ROS1+ TKI-Pretreated NSCLC Patients with G2032R Solvent Front MutationElzovantinib (TPX-0022) Demonstrates Confirmed Objective Response Rates of 36 and 33 Percent, Respectively, in MET TKI-Naïve NSCLC and Gastric/Gastroesophageal Junction (GEJ) Cancer Patients Harboring Genetic Alterations in MET in SHIELD-1 Study Repotrectinib Early Clinical Data in NTRK+ TKI-Naïve and TKI-Pretreated Solid Tumors to be Presented in Plenary Session on October 8 a

SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced additional details for its data presentations, including a late-breaking plenary presentation, from ongoing clinical trials for lead drug candidate, repotrectinib, and TPX-0022, a novel MET/SRC/CSF1R inhibitor. These data will be presented at the Virtual International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment o

Phase 1/2 TRIDENT-1 Enrollment Reaches Approximately 300 Patients, Including More than 50 in the ROS1-Positive TKI-naïve NSCLC Cohort (EXP-1)TPX-0022 Granted Fast Track Designation in MET Amplified Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction (GEJ) Adenocarcinoma after Prior Chemotherapy SHIELD-1 Phase 1 Expansion Cohorts Initiated TRIDENT-1, SHIELD-1 and CARE Studies Accepted for Clinical Data Presentations at Medical Conferences in OctoberFour Discovery Research Programs Ongoing with First 2 Development Candidates Targeted in 2H 2022; Goal to Achieve At Least 1 New IND Every Year Beginning in 2023Cash, Cash Equivalents, and Marketable Securities of $1.1 Billion Expect

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report second quarter financial results following the close of U.S. financial markets on August 9. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results and provide operational updates. President and CEO Athena Countouriotis, M.D., will host the call, which will include a question and answer session. The update will be accessible via audio webcast through the "Investors" section of www.tptherapeutics.com or by dialing (877) 388-2118 (in the United St

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022. Prior to Turning Point, Mr. Sabus spent 15 years in roles with increasing levels of sales responsibility at Astellas Pharma, most recently serving as the Head of Oncology leading a group of over 300 team members. In this role he provided executive leadership to scale the company's $3 billion U.S. oncology franchise by launching and growing new products. His achievements include su

SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022. Mr. Sun currently serves as Senior Vice President and General Counsel at Sorrento Therapeutics, Inc, a Nasdaq-listed company, where he leads the legal function and team. Previously, he worked at Prometheus Laboratories and Hologic and served as outside general counsel to early-stage biotechnology companies. Earlier in his career, Mr

MORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors. "We are excited to welcome Barbara and Alfonso to the Syneos Health Board," said John Dineen, Chair of the Syneos Health Board of Directors. "Barbara's deep financial expertise combined with Alfonso's expansive industry knowledge and international experience bring important perspectives to an already strong Board. These two leaders will enhance the composition of our Board and support continued successful overs

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Adam Levy, Ph.D., MBA, as senior vice president of Investor Relations and Corporate Communications, effective today. Dr. Levy brings more than 20 years of experience to Turning Point, including a strong background in investor relations, corporate strategy and communications. Prior to joining Turning Point, he served as executive vice president of Corporate Development and Investor Relations at Ziopharm Oncology. Previously, Dr. Levy served as executive directo

SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr. Tombesi brings 30 years of global financial and accounting experience to Turning Point from multiple prior financial leadership roles within biotech and pharmaceutical companies, most recently serving as CFO of Epizyme, Inc. "Paolo brings very valuable global financial experience to our growing team, particularly in supporting commercial organizations and product launches," said Athena Countouriotis, M.D., pre

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors. Garry Nicholson, who is currently the interim chair, will remain on the board. Mr. Alles is an accomplished biopharmaceutical executive who led successful global oncology-focused organizations over his more than three-decade career, which includes driving growth and innovation during 15 years at Celgene until its $74-billion acquisition by Bristol Myers Squibb in 2019. President and

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Kumar Srinivasan, Ph.D., MBA, as executive vice president and chief business officer, effective June 1. Dr. Srinivasan has over 20 years of experience in pharmaceutical and biotechnology companies, most recently as vice president and global head of business development for the BioPharmaceutical business unit of AstraZeneca. "As we advance now four clinical stage drug candidates and enhance our pipeline for the future, Kumar brings deep expertise to help guide o

Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), and the receipt of merger control clearance from the Federal Cartel Office of Germany ("FCO"), in connection with the previously announced offer (the "Offer") to acquire all outstanding shares of common stock of Turning Point at a price of $76.00 per share in an all-cash transaction for total consideration of approximately $4.1 billion. The expiration of the HSR Act waiting period occurred at 11:59 p.m. Eastern Time on August 15, 2022, and the FCO cleara

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193  in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58 thousand shares, closed regular trading session at $15.67. IN8bio (NASDAQ:INAB) provided a clinical update from the ongoing Phase 1 trial of INB-100, an allogeneic, or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT). IN8bio shares traded in a range of $2.37 to $2.88 on a

Turning Point Therapeutics (NASDAQ:TPTX) has received positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed in the second quarter. The pre-NDA meeting was convened to discuss its planned NDA for the lead asset Repotrectinib in the treatment of ROS1+ advanced non-small cell lung cancer (NSCLC). Repotrectinib is being evaluated in the TRIDENT-1 registrational study in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) The agency has agreed with the company's plan to provide data for ROS1+ TKI-naïve and TKI-pretreated advanced NSCLC patients with at least six months of follow-up from the first post-baseline scan

Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed within the second quarter. The feedback focused on the planned patient follow-up within the ROS1+ advanced non-small cell lung cancer (NSCLC) patient cohorts of the ongoing TRIDENT-1 registrational study of repotrectinib, the company’s lead drug candidate, which is a potential best-in-class ROS1 tyrosine kinase inhibitor that has received two breakthrough therapy designations within RO

Bristol Myers Squibb (NYSE:BMY) today has announced that Rhumba Merger Sub Inc. ("Offeror"), a wholly owned subsidiary of Bristol Myers Squibb, has extended the expiration date of its offer (the "Offer") to acquire (the "Acquisition") all of the outstanding shares of common stock, par value $0.0001 per share ("Common Stock"), of Turning Point Therapeutics, Inc. (NASDAQ:TPTX), ("Turning Point") at a price of $76.00 per share, in cash, without interest, subject to any applicable withholding of taxes, pursuant to the terms of the Agreement and Plan of Merger, dated as of June 2, 2022, among Bristol Myers Squibb, Offeror and Turning Point (the "Merger Agreement"). The Acquisition is expected to

Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, and The University of Texas MD Anderson Cancer Center today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology.   The initial focus of the alliance will be Turning Point's lead drug candidate, repotrectinib, a next-generation kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors that is currently being studied in a reg

Upgrades For Western Asset Mortgage Capital Corp (NYSE:WMC), JonesTrading upgraded the previous rating of Hold to Buy. In the first quarter, Western Asset Mortgage showed an EPS of $0.01, compared to $0.10 from the year-ago quarter. The current stock performance of Western Asset Mortgage shows a 52-week-high of $4.19 and a 52-week-low of $1.10. Moreover, at the end of the last trading period, the closing price was at $1.27. Noble Capital Markets upgraded the previous rating for Comtech Telecommunications Corp (NASDAQ:CMTL) from Market Perform to Outperform. In the third quarter, Comtech Telecom showed an EPS of $0.06, compared to $0.26 from the year-ago quarter. The stock has a 52-week-hi

SVB Leerink analyst Andrew Berens downgrades Turning Point (NASDAQ:TPTX) from Outperform to Market Perform and lowers the price target from $101 to $76.

Upgrades For Ryder System Inc (NYSE:R), Wolfe Research upgraded the previous rating of Underperform to Peer Perform. Ryder System earned $3.59 in the first quarter, compared to $1.09 in the year-ago quarter. The stock has a 52-week-high of $93.05 and a 52-week-low of $61.71. At the end of the last trading period, Ryder System closed at $81.60. According to B of A Securities, the prior rating for CAE Inc (NYSE:CAE) was changed from Underperform to Neutral. For the fourth quarter, CAE had an EPS of $0.23, compared to year-ago quarter EPS of $0.17. The current stock performance of CAE shows a 52-week-high of $34.19 and a 52-week-low of $20.96. Moreover, at the end of the last trading period,

Another week and another deal with big pharma buying out a development stage oncology company. Given the real synergies to be had through young companies partnering with big pharma to leverage their manufacturing expertise and distribution networks, regulators have allowed most of them to go through and they tend to close quickly. This explains why the spread on this Bristol Myers Squibb deal for Turning Point Therapeutics has a small spread of 1.89% or 5.85% annualized if the deal closes by the end of Q3 2022. Merger activity decreased last week with five new deals announced and two deals completed. One of the five new deals announced was a potential deal in the works. Turning Point Therap